Moreover, the spliced RNA surrogate signatures of platelets were also found to be associated with the tumor tissue molecular subtype, such as EGFR and KRAS mutations in lung cancer and HER2 and MET amplifications in BC with 85–95% accuracy rates, respectively. This evidence concerns the gene KRAS and lung carcinoma.